<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595646</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00023230</org_study_id>
    <secondary_id>ZEN-10-173646US</secondary_id>
    <nct_id>NCT01595646</nct_id>
  </id_info>
  <brief_title>Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)</brief_title>
  <acronym>SL120</acronym>
  <official_title>Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine the effects of intranasally administered long-acting insulin detemir
      on cognition in persons with Alzheimer's disease (AD) or amnestic mild cognitive impairment
      (aMCI). The rationale for these studies is derived from growing evidence that insulin
      contributes to multiple brain functions, and that insulin dysregulation can contribute to AD
      pathogenesis. Thus, therapies aimed at restoring normal insulin signaling in the CNS may have
      beneficial effects on brain function. Intranasal administration of insulin increases insulin
      signaling in the brain without raising peripheral levels and causing hypoglycemia. Insulin
      detemir is an insulin analogue that may have better action in brain than other insulin
      formulations because of its albumin binding properties. The investigators will test the
      therapeutic effects of intranasally-administered insulin detemir in a study in which
      participants will receive insulin detemir, regular insulin, or placebo over a four month
      period. The investigators will test the hypothesis that insulin and insulin detemir will both
      improve memory and daily functioning in persons with AD/aMCI compared with placebo, but that
      insulin detemir will have the greatest effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well-known that insulin, a hormone that is naturally secreted by the pancreas, plays an
      important physiological role by regulating blood sugar levels in the body. Researchers now
      know that insulin plays many important roles in the brain as well. Insulin seems to be
      especially active in the part of the brain that corresponds to learning and memory. Studies
      have shown that when people have insufficient insulin in the brain (which, for example, is
      the case with Type-II diabetes), they are increasingly at risk to develop memory problems and
      Alzheimer's disease. In a past study, the investigators administered intravenous insulin to
      participants and found that it improves memory. However, that particular method would not be
      a practical intervention for people with Alzheimer's disease due to the risks of hypoglycemia
      or exacerbation of insulin resistance. Instead, the investigators use an &quot;intranasal&quot; method
      of administration, in which the insulin is inserted into a device, and administered
      intranasally. In this method, the insulin travels directly to the brain, and bypasses the
      body. Past studies have also demonstrated that this can be a reliable way to improve memory,
      and it does not change the body's blood glucose levels.

      In our past studies, investigators have used regular insulin, which lasts about 3-4 hours and
      creates a similar &quot;spike&quot; in insulin that one would have after eating a meal. However, in
      normal physiology, the pancreas also releases small and more constant &quot;pulses&quot; of insulin
      throughout the day and night, establishing a base level of insulin. Accordingly, several
      longer-lasting types of insulin are now available that last closer to 10-12 hours, mimicking
      that basal level of insulin. The current study uses a long-lasting type of insulin called
      &quot;insulin detemir,&quot; to determine if learning and memory will benefit from a more consistent
      supplement of insulin. The investigators want to determine whether this treatment can benefit
      people who already have a memory impairment—either they have a diagnosis of Alzheimer's
      disease (AD) or have a mild cognitive impairment (MCI), a condition that precedes Alzheimer's
      disease. The investigators will examine cognition, daily function, cerebral blood flow, and
      different markers of Alzheimer's disease that are in the blood and cerebral spinal fluid
      (CSF) as outcome measures.

      The investigators have these specific aims:

        1. We will test the hypothesis that compared to placebo, four months of treatment with
           intranasal insulin or insulin detemir will improve cognition and function in adults with
           AD or MCI, but that greater effects will be observed for insulin detemir.

        2. We will examine the effects of intranasal insulin and insulin detemir on cerebral blood
           flow in adults with AD or MCI.

        3. We will examine the effects of intranasal insulin and insulin detemir on CSF Aβ, tau and
           inflammatory markers in adults with AD or MCI.

      To examine these hypotheses, the investigators are recruiting approximately 90 participants
      who have been diagnosed with AD or mild cognitive impairment. They will be randomly selected
      to take a placebo (saline), insulin detemir, or insulin. Cognition, the level of daily
      functioning, glucose tolerance, and cerebral blood flow will be tested before they begin the
      study drug, and after 16 weeks of the study drug. Some participants will also undergo a
      lumbar puncture both before beginning study drug and after 16 weeks of taking the study drug.

      Statistical analysis will follow an intent-to-treat (ITT) approach; that is, subjects will be
      analyzed in their original randomized group regardless of adherence to group assignment. A
      completer analysis will also be performed, including only those subjects who successfully
      complete the treatment phase. Missing data will be handled using multiple imputation linear
      regression. We will conduct secondary analyses on other measures of cognition, daily
      function, cerebral blood flow, and CSF biomarkers. For ASL-MRI, following coregistration and
      processing, parametric maps will be generated to determine regional CBF values by treatment
      group. Secondary analyses will also examine treatment duration (2-month vs. 4-month) for all
      relevant outcomes. All models will be adjusted for age and an index of peripheral insulin
      sensitivity (derived from 120-minute OGTT glucose and insulin values) if statistically
      warranted, and posthoc contrasts will be performed when appropriate. Secondary analyses will
      also evaluate whether treatment response of cognition, daily function, CSF and plasma
      markers, and insulin differ according to APOE4 genotype. Although these analyses will be
      exploratory due to possible limited APOE4 by treatment arm cell size, the data will be
      examined for statistical trends that warrant further exploration in larger trials. Other
      secondary analyses will examine associations among treatment-related outcomes using scores
      derived from multiple regression of data collected during the treatment phase residualized
      with respect to baseline values.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">March 12, 2015</completion_date>
  <primary_completion_date type="Actual">March 12, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verbal Memory Composite</measure>
    <time_frame>Change from Baseline in Verbal Memory at 16 weeks</time_frame>
    <description>The composite will consist of the sum of Z scores for Delayed Story Recall and Buschke Selective Reminding Test. In the Story Recall test subjects listen to a story containing 44 informational bits that is read once. Subjects will be asked to recall the story immediately after the reading and after a 20-min delay. Credit is awarded for each bit recalled verbatim or accurately paraphrased. The Buschke Selective Reminding Test measures verbal memory through multiple trials of a list learning task. A list of 12 words is audibly presented to the subject, and subjects recall as many words as possible. On subsequent trials, subjects are only told those words they omitted on the previous trial. The procedure continues until the subject recalls all words on two successive trials or to the twelfth trial. After a 30-minute delay, subjects recall as many items as possible. Number of items recalled after the delay will be summed. Higher scores indicate better performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral Spinal Fluid (CSF) Biomarkers of AD</measure>
    <time_frame>Change from Baseline in CSF Biomarkers at 16 Weeks</time_frame>
    <description>CSF Abeta (Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio</measure>
    <time_frame>Change from Baseline in CSF Biomarkers at 16 Weeks</time_frame>
    <description>CSF Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject. A pre and post ratio of TTau-P181/Abeta42 will be given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Ability</measure>
    <time_frame>baseline, month 2, and month 4</time_frame>
    <description>Subjects will have a collateral informant (i.e., spouse or friend) rate the subjects' ability to carry out activities of daily living on the Dementia Severity Rating Scale. The Dementia Severity Rating Scale is made up of sub-scales and the scores from each are summed to produce one score. The scale assess memory, ability to get from place to place, and speech and language each with a range from 0-6; recognition of family members and social and community both having a range from 0-5; orientation of time, orientation to place, ability to make decisions, home activities and responsibilities, and control of urination and bowels each having a range of 0-4; personal care- cleanliness and eating both with a range of 0-3. The total score range is from 0-54 and lower scores denotes better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision</measure>
    <time_frame>Baseline, Month 2 and Month 4</time_frame>
    <description>This cognitive screening measure contains measures of confrontational naming, following commands, constructional praxis, ideational praxis, orientation, and language production and comprehension. Total scores range from 0-70, with higher scores indicating greater cognitive impairment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Executive Function Composite</measure>
    <time_frame>Change from Baseline in Executive Functioning at 16 Weeks</time_frame>
    <description>Sum of Z Scores from Dot Counting Test (test of executive functioning) and Benton Visual Retention Test Form F&amp;G (a test of visual working memory)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Biomarkers of AD</measure>
    <time_frame>Change from Baseline in Plasma Biomarkers at 16 Weeks</time_frame>
    <description>Plasma Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cerebral Blood Flow</measure>
    <time_frame>Change from Baseline in Cerebral Blood Flow at 16 Weeks</time_frame>
    <description>Functional MRI and arterial-spin labeling perfusion MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose Tolerance</measure>
    <time_frame>Change from Baseline in Glucose Tolerance at 16 Weeks</time_frame>
    <description>Subjects will undergo oral glucose tolerance test (OGTT) to assess glucose tolerance</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo taken twice per day via intranasal route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Detemir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20IU Insulin, administered twice per day (40IU total per day) via intranasal route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline, administered intranasally twice per day for a 16 week duration</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin detemir</intervention_name>
    <description>20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
    <arm_group_label>Insulin Detemir</arm_group_label>
    <other_name>Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
    <arm_group_label>Insulin</arm_group_label>
    <other_name>Novolin R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 50-89

          -  Diagnosed with mild cognitive impairment, or mild/moderate AD

        Exclusion Criteria:

          -  Excessively high or low blood pressure, heart rate

          -  Pre-existing diabetes not controlled by exercise/diet

          -  Previous/current use of insulin

          -  Significant elevations in lipids, liver enzymes

          -  Menstrual period within the last 12 months

          -  Significant neurological or medical disorder (other than AD)

          -  Significant use of nasal decongestants

          -  Current use of anti-psychotic, anti-convulsive, anxiolytic, glucocorticoids, or
             sedative medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Craft, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Hospital</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System - American Lake Division</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98493</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>January 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2018</results_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Memory</keyword>
  <keyword>Intranasal insulin</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data with other researchers.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline</title>
          <description>Saline: Saline, administered intranasally twice per day for a 16 week duration</description>
        </group>
        <group group_id="P2">
          <title>Insulin Detemir</title>
          <description>20IU of Insulin Detemir taken twice per day (40IU total per day)
Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
        </group>
        <group group_id="P3">
          <title>Insulin</title>
          <description>20IU Insulin, administered twice per day (40IU total per day)
Insulin: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline</title>
          <description>Saline: Saline, administered intranasally twice per day for a 16 week duration</description>
        </group>
        <group group_id="B2">
          <title>Insulin Detemir</title>
          <description>20IU of Insulin Detemir taken twice per day (40IU total per day)
Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
        </group>
        <group group_id="B3">
          <title>Insulin</title>
          <description>20IU Insulin, administered twice per day (40IU total per day)
Insulin: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="61" upper_limit="75"/>
                    <measurement group_id="B2" value="66" lower_limit="62" upper_limit="70"/>
                    <measurement group_id="B3" value="68" lower_limit="56" upper_limit="80"/>
                    <measurement group_id="B4" value="68" lower_limit="56" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Verbal Memory Composite</title>
        <description>The composite will consist of the sum of Z scores for Delayed Story Recall and Buschke Selective Reminding Test. In the Story Recall test subjects listen to a story containing 44 informational bits that is read once. Subjects will be asked to recall the story immediately after the reading and after a 20-min delay. Credit is awarded for each bit recalled verbatim or accurately paraphrased. The Buschke Selective Reminding Test measures verbal memory through multiple trials of a list learning task. A list of 12 words is audibly presented to the subject, and subjects recall as many words as possible. On subsequent trials, subjects are only told those words they omitted on the previous trial. The procedure continues until the subject recalls all words on two successive trials or to the twelfth trial. After a 30-minute delay, subjects recall as many items as possible. Number of items recalled after the delay will be summed. Higher scores indicate better performance.</description>
        <time_frame>Change from Baseline in Verbal Memory at 16 weeks</time_frame>
        <population>The study is in data analysis and manuscript write-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Saline: Saline, administered intranasally twice per day for a 16 week duration</description>
          </group>
          <group group_id="O2">
            <title>Insulin Detemir</title>
            <description>20IU of Insulin Detemir taken twice per day (40IU total per day)
Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
          </group>
          <group group_id="O3">
            <title>Insulin</title>
            <description>20IU Insulin, administered twice per day (40IU total per day)
Insulin: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Memory Composite</title>
          <description>The composite will consist of the sum of Z scores for Delayed Story Recall and Buschke Selective Reminding Test. In the Story Recall test subjects listen to a story containing 44 informational bits that is read once. Subjects will be asked to recall the story immediately after the reading and after a 20-min delay. Credit is awarded for each bit recalled verbatim or accurately paraphrased. The Buschke Selective Reminding Test measures verbal memory through multiple trials of a list learning task. A list of 12 words is audibly presented to the subject, and subjects recall as many words as possible. On subsequent trials, subjects are only told those words they omitted on the previous trial. The procedure continues until the subject recalls all words on two successive trials or to the twelfth trial. After a 30-minute delay, subjects recall as many items as possible. Number of items recalled after the delay will be summed. Higher scores indicate better performance.</description>
          <population>The study is in data analysis and manuscript write-up.</population>
          <units>Change in Z score memory composite</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.31247583" spread=".23"/>
                    <measurement group_id="O2" value=".33390008" spread=".23"/>
                    <measurement group_id="O3" value="-.05181561" spread=".22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Spinal Fluid (CSF) Biomarkers of AD</title>
        <description>CSF Abeta (Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject.</description>
        <time_frame>Change from Baseline in CSF Biomarkers at 16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Saline: Saline, administered intranasally twice per day for a 16 week duration</description>
          </group>
          <group group_id="O2">
            <title>Insulin Detemir</title>
            <description>20IU of Insulin Detemir taken twice per day (40IU total per day)
Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
          </group>
          <group group_id="O3">
            <title>Insulin</title>
            <description>20IU Insulin, administered twice per day (40IU total per day)
Insulin: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Spinal Fluid (CSF) Biomarkers of AD</title>
          <description>CSF Abeta (Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abeta42 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.5" spread="148.4"/>
                    <measurement group_id="O2" value="408.5" spread="196.9"/>
                    <measurement group_id="O3" value="305.5" spread="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abeta 42 Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384" spread="212"/>
                    <measurement group_id="O2" value="381.8" spread="227.8"/>
                    <measurement group_id="O3" value="325" spread="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tau Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7" spread="27"/>
                    <measurement group_id="O2" value="118.3" spread="49.1"/>
                    <measurement group_id="O3" value="132.3" spread="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tau Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.1" spread="36.8"/>
                    <measurement group_id="O2" value="107.6" spread="56"/>
                    <measurement group_id="O3" value="152.2" spread="106.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tau-P181 Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1" spread="33.1"/>
                    <measurement group_id="O2" value="63.9" spread="28"/>
                    <measurement group_id="O3" value="74" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tau-P181 Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.17" spread="25.3"/>
                    <measurement group_id="O2" value="64.1" spread="19.8"/>
                    <measurement group_id="O3" value="68.5" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio</title>
        <description>CSF Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject. A pre and post ratio of TTau-P181/Abeta42 will be given.</description>
        <time_frame>Change from Baseline in CSF Biomarkers at 16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Saline: Saline, administered intranasally twice per day for a 16 week duration</description>
          </group>
          <group group_id="O2">
            <title>Insulin Detemir</title>
            <description>20IU of Insulin Detemir taken twice per day (40IU total per day)
Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
          </group>
          <group group_id="O3">
            <title>Insulin</title>
            <description>20IU Insulin, administered twice per day (40IU total per day)
Insulin: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio</title>
          <description>CSF Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject. A pre and post ratio of TTau-P181/Abeta42 will be given.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TTau-P181/Abeta42 ratio Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".27" spread="19"/>
                    <measurement group_id="O2" value=".23" spread=".22"/>
                    <measurement group_id="O3" value=".27" spread=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tau-P181/Abeta42 ratio Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".30" spread=".21"/>
                    <measurement group_id="O2" value=".23" spread=".16"/>
                    <measurement group_id="O3" value=".23" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Ability</title>
        <description>Subjects will have a collateral informant (i.e., spouse or friend) rate the subjects' ability to carry out activities of daily living on the Dementia Severity Rating Scale. The Dementia Severity Rating Scale is made up of sub-scales and the scores from each are summed to produce one score. The scale assess memory, ability to get from place to place, and speech and language each with a range from 0-6; recognition of family members and social and community both having a range from 0-5; orientation of time, orientation to place, ability to make decisions, home activities and responsibilities, and control of urination and bowels each having a range of 0-4; personal care- cleanliness and eating both with a range of 0-3. The total score range is from 0-54 and lower scores denotes better outcomes.</description>
        <time_frame>baseline, month 2, and month 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Saline placebo taken twice per day via intranasal route.
Saline: Saline, administered intranasally twice per day for a 16 week duration</description>
          </group>
          <group group_id="O2">
            <title>Insulin Detemir</title>
            <description>20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
          </group>
          <group group_id="O3">
            <title>Insulin</title>
            <description>20IU Insulin, administered twice per day (40IU total per day) via intranasal route
Insulin: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Ability</title>
          <description>Subjects will have a collateral informant (i.e., spouse or friend) rate the subjects' ability to carry out activities of daily living on the Dementia Severity Rating Scale. The Dementia Severity Rating Scale is made up of sub-scales and the scores from each are summed to produce one score. The scale assess memory, ability to get from place to place, and speech and language each with a range from 0-6; recognition of family members and social and community both having a range from 0-5; orientation of time, orientation to place, ability to make decisions, home activities and responsibilities, and control of urination and bowels each having a range of 0-4; personal care- cleanliness and eating both with a range of 0-3. The total score range is from 0-54 and lower scores denotes better outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="6.9"/>
                    <measurement group_id="O2" value="8.7" spread="6.7"/>
                    <measurement group_id="O3" value="7.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="6.7"/>
                    <measurement group_id="O2" value="9.7" spread="7.3"/>
                    <measurement group_id="O3" value="9.7" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="7.1"/>
                    <measurement group_id="O2" value="9.1" spread="7.5"/>
                    <measurement group_id="O3" value="10.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision</title>
        <description>This cognitive screening measure contains measures of confrontational naming, following commands, constructional praxis, ideational praxis, orientation, and language production and comprehension. Total scores range from 0–70, with higher scores indicating greater cognitive impairment.</description>
        <time_frame>Baseline, Month 2 and Month 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Saline placebo taken twice per day via intranasal route.
Saline: Saline, administered intranasally twice per day for a 16 week duration</description>
          </group>
          <group group_id="O2">
            <title>Insulin Detemir</title>
            <description>20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
          </group>
          <group group_id="O3">
            <title>Insulin</title>
            <description>20IU Insulin, administered twice per day (40IU total per day) via intranasal route
Insulin: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
          </group>
        </group_list>
        <measure>
          <title>The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision</title>
          <description>This cognitive screening measure contains measures of confrontational naming, following commands, constructional praxis, ideational praxis, orientation, and language production and comprehension. Total scores range from 0–70, with higher scores indicating greater cognitive impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="11.7"/>
                    <measurement group_id="O2" value="21.6" spread="13.7"/>
                    <measurement group_id="O3" value="19.8" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="11.8"/>
                    <measurement group_id="O2" value="23.4" spread="17.1"/>
                    <measurement group_id="O3" value="21.8" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" spread="13.7"/>
                    <measurement group_id="O2" value="19.5" spread="12.9"/>
                    <measurement group_id="O3" value="22.6" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Executive Function Composite</title>
        <description>Sum of Z Scores from Dot Counting Test (test of executive functioning) and Benton Visual Retention Test Form F&amp;G (a test of visual working memory)</description>
        <time_frame>Change from Baseline in Executive Functioning at 16 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Biomarkers of AD</title>
        <description>Plasma Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject.</description>
        <time_frame>Change from Baseline in Plasma Biomarkers at 16 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cerebral Blood Flow</title>
        <description>Functional MRI and arterial-spin labeling perfusion MRI</description>
        <time_frame>Change from Baseline in Cerebral Blood Flow at 16 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Glucose Tolerance</title>
        <description>Subjects will undergo oral glucose tolerance test (OGTT) to assess glucose tolerance</description>
        <time_frame>Change from Baseline in Glucose Tolerance at 16 Weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saline</title>
          <description>Saline: Saline, administered intranasally twice per day for a 16 week duration</description>
        </group>
        <group group_id="E2">
          <title>Insulin Detemir</title>
          <description>20IU of Insulin Detemir taken twice per day (40IU total per day)
Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)</description>
        </group>
        <group group_id="E3">
          <title>Insulin</title>
          <description>20IU Insulin, administered twice per day (40IU total per day)
Insulin: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>PT experienced chest pain during MRI.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Congestion</sub_title>
                <description>PT reported head congestion.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cold &amp; Flu Symptoms</sub_title>
                <description>PT reported having symptoms resembling a cold or flu.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>PT began to feel some anxiety during the MRI scan.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suzanne Craft, PhD</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>3366-713-8830</phone>
      <email>suzcraft@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

